Selection and use of immunosuppressive therapies after liver transplantation: current German practice. Issue 5 (31st March 2016)

• Record Type: Journal Article
• Authors: Herzer, Kerstin; Strassburg, Christian P.; Braun, Felix; Engelmann, Cornelius; Guba, Markus; Lehner, Frank; Nadalin, Silvio; Pascher, Andreas; Scherer, Marcus N.; Schnitzbauer, Andreas A.; Zimmermann, Tim; Nashan, Björn; Sterneck, Martina
• Is Part Of: Clinical transplantation. Volume 30:Issue 5(2016)
• Page Start: 487
• Page End: 501
• Publication Date: 2016-03-31
• Subjects: antiproliferative drugs -- calcineurin inhibitors -- everolimus -- immunosuppression -- induction -- liver transplantation -- mycophenolate mofetil -- steroids; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ctr.12708
• Languages: English
• ISSNs: 0902-0063

Abstract

Abstract: In recent years, immunosuppression (IS) after liver transplantation (LT) has become increasingly diversified as the choice of agents has expanded and clinicians seek to optimize the balance of immunosuppressive potency with the risk of adverse events in individual patients. Calcineurin inhibitors (CNIs) are the primary agents used for patients undergoing liver transplantation. Other therapeutic agents like interleukin‐2 receptor antagonists are not universally administered, but can be considered for the delay or reduction in CNI exposure. An early addition of mycophenolate mofetil (MMF) or the mTOR inhibitor everolimus also allows for the reduction in the CNI dose. To reduce the risk of malignancy, in particular of skin tumors, as well as to prevent the deterioration of renal function, everolimus‐based therapy may be advantageous. Apart from patients with autoimmune hepatitis, steroids are withdrawn within 3–6 months after transplantation. Overall, immunosuppression can only be standardized in a limited proportion of patients due to specific clinical requirements and risk factors. Future studies should attempt to refine accurate individualization of the immunosuppressive regimen in specific difficult‐to‐treat patient subpopulations.